Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Odevixibat by Ipsen for Biliary Atresia: Likelihood of Approval
Odevixibat is under clinical development by Ipsen and currently in Phase III for Biliary Atresia. According to GlobalData, Phase III...